Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: APS Clear all
Completed Phase 2 Interventional Results available

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

NCT00715078
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 22, 2026, 5:53 AM EDT
Completed No phase listed Observational

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

NCT07477756
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Withdrawn Phase 2 Interventional

Study of Metformin With Simvastatin for Men With Prostate Carcinoma

NCT01561482
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Metformin, Simvastatin
Drug
Lead sponsor
Nicholas Mitsiades
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Phase 4 Interventional

Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen

NCT05512754
View directory record Official record
Conditions
Elevated Serum PSA
Interventions
Ibuprofen 400 mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional

Spaced Education to Optimize Prostate Cancer Screening

NCT01168323
View directory record Official record
Conditions
Prostate Cancer
Interventions
Online spaced education
Behavioral
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Jul 22, 2026, 5:53 AM EDT
Not listed Phase 1 Interventional

Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients

NCT02058680
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA/IL-2/GM-CSF
Biological
Lead sponsor
OncBioMune Pharmaceuticals
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Not applicable Interventional Results available

Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

NCT00773773
View directory record Official record
Conditions
Prostate Cancer, Elevated Prostate Specific Antigen (PSA)
Interventions
serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
4
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Phase 4 Interventional

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT05629494
View directory record Official record
Conditions
Prostate Cancer, Prostate Inflammation, PSA
Interventions
Ibuprofen 400 mg, TID, PSA test
Drug · Diagnostic Test
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Jul 22, 2026, 5:53 AM EDT
Active, not recruiting Phase 2 Interventional

ArtemiCoffee in Patients With Rising PSA

NCT05478239
View directory record Official record
Conditions
Prostate Cancer
Interventions
ArtemiCoffee
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

NCT02680041
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-fluciclovine PET CT
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)

NCT00840294
View directory record Official record
Conditions
Elevated Prostate Specific Antigen
Interventions
Ciprofloxacin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

NCT01317199
View directory record Official record
Conditions
Prostate Cancer
Interventions
Muscadine Plus Grape Skin Extract, Low-dose MPX, High-dose MPX, Placebo oral capsule
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601
View directory record Official record
Conditions
Prostate Cancer
Interventions
CEP-701
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 4 Interventional Results available

Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

NCT00596453
View directory record Official record
Conditions
Prostate Infections
Interventions
Ciprofloxacin hydrochloride, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

NCT00001266
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Suramin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:53 AM EDT
Not listed No phase listed Observational

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

NCT00850941
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
3
States / cities
Albuquerque, New Mexico • Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT01220973
View directory record Official record
Conditions
Prostate Cancer
Interventions
atorvastatin calcium, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • Camden, New Jersey • Hamilton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Docetaxel, TroVax
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting No phase listed Observational

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

NCT06804785
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA

NCT01521949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Acai Juice Product
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT01386437
View directory record Official record
Conditions
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

NCT01483586
View directory record Official record
Conditions
Prostate Cancer
Interventions
Kanglaite gelcap
Drug
Lead sponsor
KangLaiTe USA
Industry
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Metformin Prostate Cancer Adjuvant Trial

NCT02176161
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Recurrent
Interventions
Metformin Hydrochloride Extended Release 750mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 4 Interventional

iPACK Block With Dexamethasone For Total Knee Replacement

NCT04917055
View directory record Official record
Conditions
Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
Interventions
ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 22, 2026, 5:53 AM EDT